351 related articles for article (PubMed ID: 24060052)
1. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.
Lau CP; Huang L; Wong KC; Kumta SM
Connect Tissue Res; 2013; 54(6):439-49. PubMed ID: 24060052
[TBL] [Abstract][Full Text] [Related]
2. Effect of water-soluble P-chitosan and S-chitosan on human primary osteoblasts and giant cell tumor of bone stromal cells.
Tang T; Zhang G; Lau CP; Zheng LZ; Xie XH; Wang XL; Wang XH; He K; Patrick Y; Qin L; Kumta SM
Biomed Mater; 2011 Feb; 6(1):015004. PubMed ID: 21205994
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone.
Cheng YY; Huang L; Lee KM; Xu JK; Zheng MH; Kumta SM
Calcif Tissue Int; 2004 Jul; 75(1):71-7. PubMed ID: 15037971
[TBL] [Abstract][Full Text] [Related]
4. Denosumab Induces Neoplastic Stromal Cell Apoptosis
Chen X; Ye F; He H; Chen G; Chen Z; Ye E; He B; Yang Y; Zhang J
Curr Cancer Drug Targets; 2024; 24(5):565-578. PubMed ID: 37961860
[TBL] [Abstract][Full Text] [Related]
5. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
6. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
Cowan RW; Singh G; Ghert M
J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
[TBL] [Abstract][Full Text] [Related]
7. Denosumab for the treatment of giant cell tumor of the bone.
Brodowicz T; Hemetsberger M; Windhager R
Future Oncol; 2015; 11(13):1881-94. PubMed ID: 26161925
[TBL] [Abstract][Full Text] [Related]
8. Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone.
Lau CP; Huang L; Tsui SK; Ng PK; Leung PY; Kumta SM
J Orthop Res; 2011 Mar; 29(3):403-13. PubMed ID: 20886653
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2.
Tsubaki M; Satou T; Itoh T; Imano M; Yanae M; Kato C; Takagoshi R; Komai M; Nishida S
Mol Cell Endocrinol; 2012 Sep; 361(1-2):219-31. PubMed ID: 22579611
[TBL] [Abstract][Full Text] [Related]
10. A mouse model of luciferase-transfected stromal cells of giant cell tumor of bone.
Lau CP; Wong KC; Huang L; Li G; Tsui SK; Kumta SM
Connect Tissue Res; 2015 Nov; 56(6):493-503. PubMed ID: 26327464
[TBL] [Abstract][Full Text] [Related]
11. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors.
Atkins GJ; Haynes DR; Graves SE; Evdokiou A; Hay S; Bouralexis S; Findlay DM
J Bone Miner Res; 2000 Apr; 15(4):640-9. PubMed ID: 10780856
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of osteogenic differentiation in stromal cells of giant cell tumour of bone by zoledronic acid.
Yang T; Zheng XF; Li M; Lin X; Yin QS
Asian Pac J Cancer Prev; 2013; 14(9):5379-83. PubMed ID: 24175830
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.
Viereck V; Emons G; Lauck V; Frosch KH; Blaschke S; Gründker C; Hofbauer LC
Biochem Biophys Res Commun; 2002 Mar; 291(3):680-6. PubMed ID: 11855844
[TBL] [Abstract][Full Text] [Related]
14. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
[TBL] [Abstract][Full Text] [Related]
15. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
16. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression.
Ng PK; Tsui SK; Lau CP; Wong CH; Wong WH; Huang L; Kumta SM
J Cell Biochem; 2010 May; 110(2):438-46. PubMed ID: 20225273
[TBL] [Abstract][Full Text] [Related]
17. RANKL, denosumab, and giant cell tumor of bone.
Thomas DM
Curr Opin Oncol; 2012 Jul; 24(4):397-403. PubMed ID: 22581354
[TBL] [Abstract][Full Text] [Related]
18. Antineoplastic activity of zoledronic acid and denosumab.
Zwolak P; Dudek AZ
Anticancer Res; 2013 Aug; 33(8):2981-8. PubMed ID: 23898050
[TBL] [Abstract][Full Text] [Related]
19. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
20. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
Thomas D; Henshaw R; Skubitz K; Chawla S; Staddon A; Blay JY; Roudier M; Smith J; Ye Z; Sohn W; Dansey R; Jun S
Lancet Oncol; 2010 Mar; 11(3):275-80. PubMed ID: 20149736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
